RxDoctor Payments DataLook up a doctor →

Steven Kang, MD

Clinical Cardiac Electrophysiology · Oakland, CANPI 1851320162

Payments from drug & device makers

$611,680in general payments, 2019–2025

Across 574 payments — averaging $1065.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$296K
  • Johnson & Johnson$264K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
  • Novartis$9K
  • Irhythm Technologies, Inc.$5K
  • Sanofi-aventis U.S. LLC$3K
  • plus $11K from 15 others

What the payments were for

  • Consulting fees$22,8155%
  • Speaking & faculty fees$345,80580%
  • Travel & lodging$42,41510%
  • Food & beverage$20,5685%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611,680 in reported general payments places this provider in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$383,302
Medicare patients
890
Services billed
3,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban328$374,559
EliquisApixaban250$318,196
MultaqDronedarone Hcl84$86,141
JardianceEmpagliflozin67$65,262
EntrestoSacubitril/Valsartan29$49,768
Flecainide Acetate185$9,196
FarxigaDapagliflozin Propanediol14$8,253
Dofetilide11$5,130
Metoprolol Succinate278$4,417
Diltiazem 24hr Er (Cd)Diltiazem Hcl105$2,717
Amiodarone Hcl67$1,946
Propafenone Hcl ErPropafenone Hcl22$1,890
Propafenone Hcl43$1,767
Atorvastatin Calcium80$1,084
Carvedilol101$1,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$264,237$374,559328 claims
Sanofi-aventis U.S. LLCMultaq$3,462$86,14184 claims
Boehringer IngelheimJardiance$93$65,26267 claims
NovartisEntresto$9,131$49,76829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →